期刊
BJU INTERNATIONAL
卷 110, 期 -, 页码 14-29出版社
WILEY
DOI: 10.1111/j.1464-410X.2012.11430.x
关键词
prostate cancer; treatment; survival; chemotherapy; immunotherapy; castration-resistant prostate cancer
The treatment of metastatic and castration-resistant prostate cancer (CRPC) has advanced considerably from the era where it was considered that the disease was resistant to chemotherapy. Cytotoxic chemotherapy involving docetaxel is now used routinely as a first-line therapy after failed first-and second-line androgen deprivation in advanced disease, improving quality of life and to a limited extent, survival in patients with advanced prostate cancer. The cytotoxic taxane, cabazitaxel has also become a second-line treatment option for patients with CRPC failing previous docetaxel therapy. Additionally, a broad range of agents are now available or under development including immune-based therapies (cellular therapies and vaccines), bone-targeting agents (anti-osteolytic and anti-tumour therapies) and molecular-based agents targeting cellular control mechanisms. Most of these remain experimental but on-going pharmacological development will inevitably provide urologists and urological oncologists with a broader range of therapeutic options for better cancer management in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据